The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.
本公开涉及式(I)的化合物,以及其药学上可接受的盐和立体异构体。本公开还涉及制备这些化合物的方法,包含这些化合物的组合物,以及将这些化合物用作受体
酪氨酸激酶的
抑制剂的方法,特别是ErbB受体的致癌突变体,例如在癌症治疗中的应用。